Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $94
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $94
Chardan Capital維持對CRISPR Therapeutics的買入評級，將價格目標下調至94美元。
Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $112 to $94.
Chardan Capital分析師Geulah Livshits維持對crispr therapeutics (納斯達克:CRSP)的買入評級，並將價格目標下調從112美元至94美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。